Virgin Media O2 Selects Mavenir for its Open RAN Deployment
17.4.2023 10:00:00 EEST | Business Wire | Press release
Virgin Media O2 has selected Mavenir, the Network Software Provider building the future of networks with cloud-native solutions that run on any cloud, as its Open Radio Access Network (Open RAN) vendor. Mavenir will also be the prime integrator, providing its Open virtualised Radio Access Network (Open vRAN) solution for sites on Virgin Media O2’s network.
Virgin Media O2 will work with Mavenir to roll out a scalable Open vRAN solution as part of its network evolution plans and adopt a more flexible and cloud-native architecture.
Mavenir’s Open vRAN solution is built from the ground up to be cloud-native, with fully containerised microservices allowing it to be deployed easily on any cloud. Mavenir’s Open vRAN O-RAN compliant solution works on open interfaces supporting O-RAN Split 7.2x and Split 2.
It further disaggregates into Distributed Unit (DU) and Centralised Unit (CU). These entities work as containerised network functions running on Commercial Off the Shelf (COTS) hardware containing Intel processors.
Designed to support multiple Fronthaul splits simultaneously, the vRAN solution provides a vendor-agnostic and future-proof architecture, leveraging Virgin Media O2’s network infrastructure assets.
Mavenir’s Open RAN system will consist of fully virtualised L1, L2 vRAN SW and will operate on Intel Xeon Scalable Processors, along with Intel vRAN Accelerator ACC100 and Intel 800 series Ethernet adapters. The delivery will also feature Mavenir’s OpenBeam™ Radios including massive MIMO, 3rd party O-RAN based Radio Units (O-RU) for open Fronthaul, network monitoring and optimisation.
Jeanie York, Chief Technology Officer at Virgin Media O2, said: “Through digitalising our networks, we’re seamlessly integrating our infrastructure to get more value from our existing assets. Extending our collaboration with Mavenir to the RAN for the first time will help us establish a future-proof Open vRAN architecture, unlocking the benefits of a multi-vendor open interface while allowing us to rapidly benefit from an end-to-end network solution.”
Pardeep Kohli, President and CEO at Mavenir, said: “Mavenir’s Open vRAN cloud-native approach presents new pathways for automated networks to deliver on the use cases and data demands of today and beyond - driving network elasticity, flexibility and best-in-class automation. The Mavenir OpenBeam radio portfolio fully complements Virgin Media O2’s full spectrum requirements and we look forward to playing an active role in unlocking network automation and openness in the RAN.”
Cristina Rodriguez, Vice President Network and Edge Group at Intel, said: “Open and virtualised RAN represents the future: a flexible and scalable software-defined network. Intel is pleased to collaborate with and be part of the Virgin Media O2 technology journey with Mavenir. Together we are delivering innovation, performance, and we are working towards more sustainable networks.”
Notes to Editors
About Virgin Media O2
Virgin Media O2 launched on 1 June 2021, combining the UK’s largest and most reliable mobile network with a broadband network offering the fastest widely-available broadband speeds. It is a customer-first organisation that brings a range of connectivity services together in one place with a clear mission: to upgrade the nation. Virgin Media O2 is the corporate brand of the 50:50 joint venture between Liberty Global and Telefónica SA, and one of the UK’s largest businesses. The company has 47 million UK connections across broadband, mobile, TV and home phone. Its own fixed network currently passes 16.1 million premises alongside a mobile network that covers 99% of the nation’s population with 4G, and more than 1,600 towns and cities with 5G services targeting 50% population coverage in 2023.
About Mavenir
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230316005006/en/
Contact information
Mavenir PR Contacts:
PR@mavenir.com
Maryvonne Tubb (US)
Emmanuela Spiteri (EMEA)
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom